Want to see SOLV full AI Analyst Report?
SOLV Stock Chart & Stats
$70.48
-$0.47(-0.68%)
At close: 4:00 PM EST
$70.48
-$0.47(-0.68%)
Day’s Range― - ―
52-Week Range$62.38 - $88.20
Previous CloseN/A
Volume531.14K
Average Volume (3M)2.13M
Market Cap
$13.36B
Enterprise Value$17.43B
Total Cash (Recent Filing)$561.00M
Total Debt (Recent Filing)$5.08B
Price to Earnings (P/E)9.4
Beta0.64
Next Earnings
Aug 06, 2026EPS Estimate
1.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.21
Shares Outstanding173,174,710
10 Day Avg. Volume1,598,729
30 Day Avg. Volume2,130,723
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit3.93
Enterprise Value/Ebitda6.33
Forecast
1Y Price Target
$83.00Price Target Upside17.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)6.55
Revenue Forecast (FY)$8.19B
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Strong ProfitabilitySustained gross and operating margin improvements reflect durable pricing, mix and cost discipline. Management targets another 50–100bps of operating margin expansion, indicating structural margin tailwinds from SKU rationalization and product mix that can support long‑term earnings power even if revenue growth lags.
Transform For The Future Cost-savings ProgramA $500M multiyear program centered on automation, system streamlining and footprint optimization is a structural initiative that reduces the company’s cost base. If executed, it sustainably improves operating leverage, enhances margin resiliency and materially supports free cash flow improvement over the medium term.
Health Information Systems (HIS) And Autonomous Coding MomentumGrowth in software-enabled RCM and AI autonomous coding shifts the mix toward higher-margin, recurring revenue. International expansion and productivity benefits for customers create structural demand, reducing reliance on cyclical consumables and improving long-term revenue quality and margin durability.
Bears Say
Weak Cash Generation / Negative Free Cash FlowA persistent gap between accounting earnings and cash flow is a material durability risk. Negative free cash flow limits flexibility to fund debt, buybacks or invest behind growth. Separation costs, tax timing and ERP phasing exacerbate conversion issues and must improve to validate profitability.
Mixed Revenue Trends And TTM DeclineStagnant or declining top-line undermines long-term growth targets and increases reliance on cost cuts and M&A. Organic growth is modest; SKU rationalization and portfolio moves have created reporting volatility that masks durable end-market demand, challenging sustainable revenue expansion.
Elevated Net Debt And Leverage VolatilityAn elevated net debt position combined with historically variable leverage reduces financial flexibility. Debt levels constrain capital allocation in adverse scenarios, heighten sensitivity to cash conversion, and make execution riskier if tariffs, separation costs or ERP timing pressure cash flow before savings fully materialize.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $62.38 and its highest was $88.20 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $13.36B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on May 05, 2026. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.353 by $0.127.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 1.89.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 173,174,710 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $1.48 in its last earnings report, beating expectations of $1.353. Following the earnings report the stock price went up 2.824%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$83.00 (17.76% Upside)
$83.00 (17.76% Upside)
Blogger Sentiment
Bullish
SOLV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 301.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.72%
12-Months-Change
Fundamentals
Return on Equity
30.71%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
SOLV Company Deck
SOLV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: Q1 results beat expectations with organic growth, EPS upside (+11% YoY), improved gross margins (+80 bps), strong segment performance (MedSurg, Dental, HIS) and tangible progress on separation, SKU rationalization, and integration of Acera. Management reiterated multiyear savings (Transform for the Future $500M) and an intent to accelerate share repurchases while maintaining full-year guidance. The primary negatives are timing and separation-related volatility: reported sales declined -3% due to acquisition/divestiture impacts, tariff and inflationary headwinds ($100M–$120M range) remain, ERP cutover phasing will drive >$100M of order timing into Q2 that reverses in Q3, and certain legacy product lines (clinician productivity solutions) face double-digit declines. Overall, most issues are described as transitory or manageable via mitigation programs and the company emphasized accelerating margin expansion and product-driven growth, supporting a constructive outlook.View all SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$83.00
▲(17.76% Upside)
Technical Analysis
DaVita
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
14.99% Insiders
19.91% Mutual Funds
29.86% Other Institutional Investors
14.29% Public Companies and
Individual Investors